In addition, therapeutic strategies targeting CTGF, such as monoclonal antibodies, have shown promising results in vitro and have been tested in large randomized clinical trials for idiopathic pulmonary fibrosis. This evidence concerns the gene CCN2 and pulmonary fibrosis.